Cargando…

Conditioning Intensity, Pre-Transplant Flow Cytometric Measurable Residual Disease, and Outcome in Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation

How conditioning intensity is related to outcomes of AML patients undergoing allografting in morphologic remission is an area of great ongoing interest. We studied 743 patients in morphologic remission and known pre-transplant measurable residual disease (MRD) status determined by multiparameter flo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morsink, Linde M., Sandmaier, Brenda M., Othus, Megan, Palmieri, Raffaele, Granot, Noa, Bezerra, Evandro D., Wood, Brent L., Mielcarek, Marco, Schoch, Gary, Davis, Chris, Flowers, Mary E. D., Deeg, H. Joachim, Appelbaum, Frederick R., Storb, Rainer, Walter, Roland B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565021/ https://www.ncbi.nlm.nih.gov/pubmed/32825022 http://dx.doi.org/10.3390/cancers12092339

Ejemplares similares

Impact of Pre-Transplant Measurable Residual Disease on Outcome of Allogeneic Hematopoietic Cell Transplantation in Adult Monosomal Karyotype AML
por: Morsink, Linde M., et al.
Publicado: (2020)

Utility of Treatment-Related Mortality (TRM) Score to Predict Outcomes of Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation
por: Zarling, Lucas C., et al.
Publicado: (2022)

Contribution of measurable residual disease status to prediction accuracy of relapse and survival in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation
por: Rodríguez-Arbolí, Eduardo, et al.
Publicado: (2022)

Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia
por: Orvain, Corentin, et al.
Publicado: (2022)

Association between Prior Cytotoxic Therapy, Antecedent Hematologic Disorder, and Outcome after Allogeneic Hematopoietic Cell Transplantation in Adult Acute Myeloid Leukemia
por: Orvain, Corentin, et al.
Publicado: (2023)

History of hematopoietic cell transplantation: challenges and progress
por: Granot, Noa, et al.
Publicado: (2020)

Prognostic factors and outcomes of severe gastrointestinal graft-vs.-host disease after allogeneic hematopoietic cell transplantation
por: Castilla-Llorente, Cristina, et al.
Publicado: (2014)

Allogeneic Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome and Concurrent Lymphoid Malignancy
por: Zimmerman, Zachary, et al.
Publicado: (2011)

Comparison of Minimal Residual Disease as Outcome Predictor for AML Patients in First Complete Remission Undergoing Myeloablative or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation
por: Walter, Roland B., et al.
Publicado: (2014)

Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma
por: Maffini, Enrico, et al.
Publicado: (2019)

Analysis of Antibiotic Exposure and Development of Acute Graft-vs-Host Disease Following Allogeneic Hematopoietic Cell Transplantation
por: Rashidi, Armin, et al.
Publicado: (2023)

Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: improved outcomes over two decades
por: Cooper, Jason P., et al.
Publicado: (2020)

Role of Comorbidities in Optimizing Decision-Making for Allogeneic Hematopoietic Cell Transplantation
por: Sorror, Mohamed L., et al.
Publicado: (2010)

Extracorporeal Photopheresis in Addition to Pentostatin in Conditioning for Canine Hematopoietic Cell Transplantation: Role in Engraftment
por: Bethge, Wolfgang A., et al.
Publicado: (2010)

Total body irradiation dose escalation decreases risk of progression and graft rejection after hematopoietic cell transplantation for myelodysplastic syndromes or myeloproliferative neoplasms
por: Monaco, Federico, et al.
Publicado: (2019)

Extracorporeal photopheresis combined with pentostatin in the conditioning regimen for canine hematopoietic cell transplantation does not prevent GVHD
por: Bethge, Wolfgang, et al.
Publicado: (2014)

cGMP production of astatine-211-labeled anti-CD45 antibodies for use in allogeneic hematopoietic cell transplantation for treatment of advanced hematopoietic malignancies
por: Li, Yawen, et al.
Publicado: (2018)

What Role Is There for Antithymocyte Globulin in Allogeneic Nonmyeloablative Canine Hematopoietic Cell Transplantation?
por: Diaconescu, Razvan, et al.
Publicado: (2005)

Treatment of Fanconi anemia patients using fludarabine and low-dose total body irradiation followed by unrelated donor hematopoietic cell transplantation
por: Thakar, Monica S, et al.
Publicado: (2010)

Reconstitution of T Cell Subsets Following Allogeneic Hematopoietic Cell Transplantation
por: Dekker, Linde, et al.
Publicado: (2020)

The Quality of Life of Adult Survivors of Childhood Hematopoietic Cell Transplant
por: Sanders, Jean E., et al.
Publicado: (2009)

Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant
por: Sandmaier, Brenda M., et al.
Publicado: (2017)

Dose-adapted post-transplant cyclophosphamide for HLA-haploidentical transplantation in Fanconi anemia
por: Thakar, Monica S., et al.
Publicado: (2017)

Transplant Center Characteristics And Survival After Allogeneic Hematopoietic Cell Transplantation In Adults
por: Majhail, Navneet S, et al.
Publicado: (2019)

Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis
por: Buckley, Sarah A., et al.
Publicado: (2017)

Yttrium-90-labeled anti-CD45 antibody followed by a reduced-intensity hematopoietic cell transplantation for patients with relapsed/refractory leukemia or myelodysplasia
por: Vo, Phuong, et al.
Publicado: (2020)

1001. Feasibility and Outcomes of a Pre-Transplant Antibiotic Allergy Evaluation Program for Allogeneic Hematopoietic Cell Transplant (HCT) Candidates
por: Liu, Catherine, et al.
Publicado: (2019)

Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience
por: Shadman, Mazyar, et al.
Publicado: (2019)

Cytotoxic Pathways in Allogeneic Hematopoietic Cell Transplantation
por: Du, Wei, et al.
Publicado: (2018)

Allogeneic hematopoietic stem-cell transplantation for myelofibrosis
por: Zhang, Lining, et al.
Publicado: (2020)

Allogeneic Hematopoietic Cell Transplantation and Cellular Therapy
por: Kim, Hee-Je, et al.
Publicado: (2021)

Pre- and Post-Transplant Quantification of Measurable (“Minimal”) Residual Disease via Multiparameter Flow Cytometry in Adult Acute Myeloid Leukemia
por: Zhou, Yi, et al.
Publicado: (2016)

Incidence, Risk Factors, and Outcomes of Idiopathic Pneumonia Syndrome after Allogeneic Hematopoietic Cell Transplantation
por: Wenger, David S., et al.
Publicado: (2020)

Hematopoietic Cell Transplantation Provides an Immune-tolerant Platform for Myoblast Transplantation in Dystrophic Dogs
por: Parker, Maura H, et al.
Publicado: (2008)

Hematopoietic Cell Transplantation for Older Patients with MDS
por: Shadman, Mazyar, et al.
Publicado: (2014)

The cellular composition and function of the bone marrow niche after allogeneic hematopoietic cell transplantation
por: Peci, Flavia, et al.
Publicado: (2022)

Hemorrhagic cystitis following allogeneic hematopoietic cell transplantation.
por: Lee, Gyeong-Won, et al.
Publicado: (2003)

Allogeneic hematopoietic stem cell transplantation in mycosis fungoides
por: Atalla, Angelo, et al.
Publicado: (2013)

Ectonucleotidases in Solid Organ and Allogeneic Hematopoietic Cell Transplantation
por: Chernogorova, Petya, et al.
Publicado: (2012)

Epigenetic therapy in allogeneic hematopoietic stem cell transplantation
por: Bashir, Qaiser, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_8dq35l17dc2ssir67lp1j4ngdq